Loren Data's SAM Daily™

FBO DAILY ISSUE OF SEPTEMBER 01, 2005 FBO #1375
SOLICITATION NOTICE

B -- Defining Molecular Subtypes of Lymphoma for Relevance to Survival, Etiology, and Diagnosis

Notice Date

8/30/2005
 

Notice Type

Solicitation Notice
 

NAICS

541990 — All Other Professional, Scientific, and Technical Services
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

Reference-Number-NCI-50162-NE
 

Response Due

9/13/2005
 

Archive Date

9/28/2005
 

Description

The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DECG), Hormonal and Reproductive Epidemiology Branch (HREB) plans to contract on a sole source basis with The University of Iowa, 200 Hawkins Drive, 6229 Roy Carver Pavilion, Iowa City, IA 52242-1009 for: Defining molecular subtypes of lymphoma for relevance to survival, etiology, and diagnosis. The acquisition is being conducted under the simplified acquisition procedures authorized in FAR Part 13. The North American Industry Classification System Code is 541990 and the business size standard is $6M. Background: The Hormonal and Reproductive Epidemiology Branch is working on a study to define molecular subtypes of lymphoma for relevance to survival, etiology, and diagnosis. The pathology specimens from the NCI-SEER Case?Control Study were collected and are being stored under a previous contract establishing the University of Iowa as the Pathology Review Center for the parent case?control study. Diffuse large B-cell lymphoma (DLBCL) is the most heterogeneous and most common type of non-Hodgkin lymphoma (NHL). Recent cDNA microarray gene expression studies have revealed two distinct DLBCL subtypes (germinal center B-cell?like DLBCL (GCB-DLBCL) and post-GCB-DLBCL) with clinical relevance, distinct normal cell counterparts, and occurrence of distinct oncogenic events. Cases expressing a set of genes characteristic of germinal center B-cells (GCB-DLBCL) appear to show markedly better clinical prognosis than those expressing a set of genes characteristic of post-germinal center, activated peripheral blood B-cells (post-GCB-DLBCL) (five-year overall survival rates: 60-75% and 15-40%, respectively). Furthermore, distinct oncogenic events in these subtypes have been demonstrated: translocation is observed in GCB-DLBCL, whereas constitutive activation of the nuclear factor-?B (NF-?B) pathway is observed in post-GCB-DLBCL. Together these findings suggest that GCB- and post-GCB-DLBCL may arise through separate pathogenetic mechanisms, yet no research on potential etiologic differences of these DLBCL subtypes has been published to-date. For the first time, identification of these DLBCL subtypes in a large-scale, epidemiologic setting is possible due to the recent demonstration of the feasibility of using immunohistochemical staining for three proteins (CD10, BCL-6, and MUM1) to classify GCB- and post-GCB-DLBCL. The goal of the present work is to classify the DLBCL cases in the NCI-SEER NHL Case?Control Study by molecular subtype (GCB- and post-GCB-DLBCL) using immunohistochemical staining; to confirm the prognostic significance of the DLBCL molecular subtypes in our large, population-based sample; and to evaluate potential etiologic differences by DLBCL molecular subtype. The pathology specimens from the study are under the authority of Dr. Mohammad Vasef. They have a collaborative arrangement to obtain the GCET antibody stain, which is not commercially available, and the laboratory has optimized the immunohistochemical staining protocol for the proteins of interest in paraffin-embedded tissues that may have undergone antigen degradation. The immunohistochemical staining to identify the molecular subtypes of DLBCL in the NCI-SEER Case?Control Study population is required to be conducted at the University of Iowa. The University of Iowa is the only known source to the NCI that can successfully complete this project. Period of Performance: one year from date of award. This is a notice of intent not a request for competitive quotation. However, if any interested party believes it can meet the above requirements, it may submit a statement of capabilities. The capability statement and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can fully meet the requirements herein. Capability statements must be received in the contracting office by 3:00 PM EDT on September 13, 2005. If you have any questions, please submit them in writing via electronic mail to Karen Gardner, Contract Specialist at gardnerka@mail.nih.gov or by fax 301-402-4513. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered with the Central Contractor Registration (CCR) at www.ccr.gov and the online Representations and Certifications Applications (ORCA) at http://orca.bpn.gov.
 

Place of Performance

Address: Iowa City, IA

Zip Code: 52242

Country: USA
 

Record

SN00882395-W 20050901/050830211812 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |